Pearl Therapeutics, a subsidiary of AstraZeneca, specializes in developing innovative respiratory therapies aimed at improving patient outcomes. Operating in the pharmaceutical and biotechnology market, Pearl Therapeutics focuses on creating advanced inhalation technology for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company serves healthcare providers and patients, leveraging its expertise in drug formulation and delivery systems to offer effective treatment options. Pearl Therapeutics generates revenue through the development and commercialization of its proprietary respiratory therapies, often in collaboration with its parent company, AstraZeneca. The business model includes research and development, clinical trials, regulatory approvals, and market distribution. By addressing unmet medical needs in respiratory care, Pearl Therapeutics aims to enhance the quality of life for patients worldwide.

Keywords: respiratory therapies, inhalation technology, COPD, asthma, drug formulation, healthcare providers, biotechnology, clinical trials, regulatory approvals, patient outcomes.